GSK to buy cancer company for USD 1.9bn
Glaxosmithkline and Sierra Oncology have agreed to terms that would bring the Canadian biotech firm into British hands.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Another acquisition is taking place in the pharmaceutical industry at large, as Glaxosmithkline (GSK) and Sierra Oncology have announced on Wednesday that they have reached an agreement, a press release reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Glaxosmithkline halts RSV trial after safety recommendation
For subscribers
